Halofuginone - The multifaceted molecule

Molecules

Volumn 20, Issue 1, 2015, Pages 573-594

  Pines, Mark ^a   Spector, Itai ^a,b  

^a VOLCANI CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Apoptosis; Autoimmunity; Fibrosis; Inflammation; Malaria; Th 17

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; HALOFUGINONE; PIPERIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANIMAL; APOPTOSIS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; SYNTHESIS;

ANIMALS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERIDINES; QUINAZOLINONES;

EID: 84921690122     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20010573     Document Type: Review

References (126)

1. Ziegler, S.; Pries, V.; Hedberg, C.; Waldmann, H. Target identification for small bioactive molecules: Finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 2013, 52, 2744-2792.
2. Kang, Y.B.; Mallikarjuna, P.R.; Fabian, D.A.; Gorajana, A.; Lim, C.L.; Tan, E.L. Bioactive molecules: Current trends in discovery, synthesis, delivery and testing. IeJSME 2013, 7 (Suppl. 1), S32-S46.
3. Jang, C.S.; Fu, F.Y.; Huang, K.C.; Wang, C.Y. Pharmacology of Ch'ang Shan (Dichroa febrifuga), a Chinese antimalarial herb. Nature 1948, 161, 400-401.
4. Kuehl, F.A.; Spencer, C.F.; Folkers, J.A. Alkaloids of Dichroa febrifuga, Lour. J. Am. Chem. Soc. 1947, 70, 2091-2093.
5. Jang, C.S.; Fu, F.Y.; Wang, C.Y.; Huang, K.C.; Lu, G.; Chou, T.C. Ch'ang Shan, a Chinese antimalarial herb. Science 1946, 103, 59, doi:10.1126/science.103.2663.59-b.
6. Koepfli, J.B.; Mead, J.F.; Brockman, J.A., Jr. An alkaloid with high antimalarial activity from Dichroa febrifuga. J. Am. Chem. Soc . 1947, 69, doi:10.1021/ja01199a513.
7. Koepfli, J.B.; Mead, J.F.; Brockman, J.A., Jr. Alkaloids of Dichroa febrifuga. I. Isolation and degradative studies. J. Am. Chem. Soc . 1949, 71, 1048-1054.
8. Coatney, G.R.; Cooper, W.C.; Culwell, W.B.; White, W.C.; Imboden, C.A., Jr. Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroa febrifuga Lour. against the Chesson strain of Plasmodium vivax. J. Natl. Malar. Soc . 1950, 9, 183-186.
9. Tang, W.; Eisenbrand, G. Chinese Drugs of Plant Origin; Springer-Verlag: Berlin, Germany, 1992; pp. 455-457.
10. Fishman, M.; Cruickshank, P.A. Febrifugine antimalarial agents. I. Pyridine analogs of febrifugine J. Med. Chem. 1970, 13, 155-156.
11. Chien, P.L.; Cheng, C.C. Structural modification of febrifugine. Some methylenedioxy analogs. J. Med. Chem. 1970, 13, 867-870.
12. De Smet, P.A.G.M. The role of plant-derived drugs and herbal medicines. Drugs 1997, 54, 801-840.
13. Baker, B.R.; Schaub, R.E.; McEvoy, F.J.; Williams, J.H. An antimalarial alkaloid from Hydrangea. J. Org. Chem. 1952, 17, 133-137.
14. Jiang, S.; Zeng, Q.; Gettayacamin, M.; Tungtaeng, A.; Wannaying, S.; Lim, A.; Hansukjariya, P.; Okunji, C.O.; Zhu, S.; Fang, D. Antimalarial activities and therapeutic properties of febrifugine analogs. Antimicrob. Agents Chemother. 2005, 49, 1169-7116.
15. Sen, D.; Banerjee, A.; Ghosh, A.K.; Chatterjee, T.K. Synthesis and antimalarial evaluation of some 4-quinazolinone derivatives based on febrifugine. J. Adv. Pharm. Technol. Res. 2010, 1, 401-405.
16. Kikuchi, H.; Yamamoto, K.; Horoiwa, S.; Hirai, S.; Kasahara, R.; Hariguchi, N.; Matsumoto, M.; Oshima, Y. Exploration of a new type of antimalarial compounds based on febrifugine. J. Med. Chem. 2006, 49, 4698-4706.
17. Kikuchi, H.; Horoiwa, S.; Kasahara, R.; Hariguchi, N.; Matsumoto, M.; Oshima, Y. Synthesis of febrifugine derivatives and development of an effective and safe tetrahydroquinazoline-type antimalarial. Eur. J. Med. Chem. 2014, 76, 10-19.
18. Sen, D.; Chatterjee, T.K. Pharmacophore modeling and 3D quantitative structure-activity relationship analysis of febrifugine analogues as potent antimalarial agent. J. Adv. Pharm. Technol. Res. 2013, 4, 50-60.
19. Takaya, Y.; Tasaka, H.; Chiba, T.; Uwai, K.; Tanitsu, M.; Kim, H.S. New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against plasmodium malaria parasite. J. Med. Chem. 1999, 42, 3163-3166.
20. Pinion, J.L.; Bilgili, S.F.; Eckman, M.K.; Hess, J.B. The effects of halofuginone and salinomycin, alone and in combination, on live performance and skin characteristics of broilers. Poult. Sci . 1995, 74, 391-397.
21. Zhang, D.F.; Sun, B.B.; Yue, Y.Y.; Yu, H.J.; Zhang, H.L.; Zhou, Q.J.; Du, A.F. Anticoccidial effect of halofuginone hydrobromide against Eimeria tenella with associated histology. Parasitol. Res. 2012, 111, 695-701.
22. Daugschies, A.; Gässlein, U.; Rommel, M. Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials. Vet. Parasitol . 1998, 76, 163-171.
23. Peeters, J.E.; Villacorta, I.; Naciri, M.; Vanopdenbosch, E. Specific serum and local antibody responses against Cryptosporidium parvum during medication of calves with halofuginone lactate. Infect. Immun. 1993, 61, 4440-4445.
24. Kamberov, Y.G.; Kim, J.; Mazitschek, R.; Kuo, W.P.; Whitman, M. Microarray profiling reveals the integrated stress response is activated by halofuginone in mammary epithelial cells. BMC Res. Notes 2011, 4, 381, doi:10.1186/1756-0500-4-381.
25. Kobayashi, S.; Ueno, M.; Suzuki, R.; Ishitani, H.; Kim, H.S.; Wataya, Y. Catalytic asymmetric synthesis of antimalarial alkaloids febrifugine and isofibrifugine and their biological activity. J. Org. Chem. 1999, 64, 6833-6841.
26. Taniguchi, T.; Ogasawara, K. A diastereocontrolled synthesis of (+)-febrifugine: A potent antimalarial piperidine alkaloid. Org. Lett. 2000, 2, 3193-3195.
27. Samant, B.S.; Sukhthankar, M.G. Synthesis and comparison of antimalarial activity of febrifugine derivatives including halofuginone. Med. Chem. 2009, 5, 293-300.
28. McLaughlin, N.P.; Evans, P. Dihydroxylation of vinyl sulfones: Stereoselective synthesis of (+)- and (-)-febrifugine and halofuginone. J. Org. Chem. 2010, 75, 518-521.
29. Takeuchi, Y.; Azuma, K.; Abe, H.; Sasaki, K.; Harayama, T. Re-revision of the stereo structure of piperidine lactone, an intermediate in the synthesis of febrifugine. Chem. Pharm. Bull. (Tokyo) 2002, 50, 1011-1012.
30. McLaughlin, N.P.; Evans, P.; Pines, M. The chemistry and biology of febrifugine and halofuginone. Bioorg. Med. Chem. 2014, 22, 1993-2004.
31. Geary, T.G.; Divo, A.A.; Jensen, J.B. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am. J. Trop. Med. Hyg . 1989, 40, 240-244.
32. Derbyshire, E.R.; Mazitschek, R.; Clardy, J. Characterization of Plasmodium liver stage inhibition by halofuginone. ChemMedChem 2012, 7, 844-849.
33. Jain, V.; Kikuchi, H.; Oshima, Y.; Sharma, A.; Yogavel, M. Structural and functional analysis of the antimalarial drug target prolyl-tRNA synthetase. J. Struct. Funct. Genomics 2014, 15, 181-190.
34. Zhou, H.; Sun, L.; Yang, X.L.; Schimmel, P. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature 2013, 494, 121-124.
35. Chapman, H.D. Milestones in avian coccidiosis research: A review. Poult. Sci . 2014, 93, 501-511.
36. Daugschies, A.; Najdrowski, M. Eimeriosis in cattle: Current understanding. J. Vet. Med. B Infect. Dis. Vet. Public Health 2005, 52, 417-427.
37. Silverlås, C.; Björkman, C.; Egenvall, A. Systematic review and meta-analyses of the effects of halofuginone against calf cryptosporidiosis. Prev. Vet. Med. 2009, 91, 73-84.
38. Folz, S.D.; Lee, B.L.; Nowakowski, L.H.; Conder, G.A. Anticoccidial evaluation of halofuginone, lasalocid, maduramicin, monensin and salinomycin. Vet. Parasitol. 1988, 28, 1-9.
39. Xie, M.Q.; Fukata, T.; Gilbert, J.M.; McDougald, L.R. Evaluation of anticoccidial drugs in chicken embryos. Parasitol. Res. 1991, 77, 595-599.
40. Fitz-Coy, S.H.; Edgar, S.A. Pathogenicity and control of Eimeria mitis infections in broiler chickens. Avian Dis. 1992, 36, 44-48.
41. Constable, P.D. Treatment of calf diarrhea: Antimicrobial and ancillary treatments. Vet. Clin. North Am. Food Anim. Pract. 2009, 25, 101-120.
42. De Waele, V.; Speybroeck, N.; Berkvens, D.; Mulcahy, G.; Murphy, T.M. Control of cryptosporidiosis in neonatal calves: Use of halofuginone lactate in two different calf rearing systems. Prev. Vet. Med. 2010, 96, 143-151.
43. Klein, P. Preventive and therapeutic efficacy of halofuginone-lactate against Cryptosporidium parvum in spontaneously infected calves: A centralised, randomised, double-blind, placebo-controlled study. Vet. J. 2008, 177, 429-431.
44. Giadinis, N.D.; Papadopoulos, E.; Panousis, N.; Papazahariadou, M.; Lafi, S.Q.; Karatzias, H. Effect of halofuginone lactate on treatment and prevention of lamb cryptosporidiosis: An extensive field trial. J. Vet. Pharmacol. Ther. 2007, 30, 578-582.
45. Shahiduzzaman, M.; Dyachenko, V.; Obwaller, A.; Unglaube, S.; Daugschies, A. Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum. Vet. Parasitol. 2009, 162, 271-277.
46. Linder, M.R.; Heckeroth, A.R.; Najdrowski, M.; Daugschies, A.; Schollmeyer, D.; Miculka, C. (2R,3S)-(+)- and (2 S,3R)-(-)-halofuginone lactate: Synthesis, absolute configuration, and activity against Cryptosporidium parvum. Bioorg. Med. Chem. Lett. 2007, 17, 4140-4143.
47. Pines, M.; Nagler, A. Halofuginone-A novel anti-fibrotic therapy. Drug Future 1996, 21, 569-599.
48. Pines, M.; Vlodavsky, I.; Nagler, A. Halofuginone-A novel anti-fibrotic therapy. Gen. Pharmacol. 1997, 30, 445-450.
49. Pines, M.; Vlodavsky, I.; Nagler, A. Halofuginone: From veterinary use to human therapy. Drug Dev. Res. 2000, 50, 371-378.
50. Pines, M. Targeting TGFβ signaling to inhibit fibroblasts activation as a therapy for fibrosis and cancer. Expt. Opin. Drug Dis. 2008, 3, 11-20.
51. Pines, M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J. Gastroenterol. 2014, 20, 14778-14786.
52. Nelson, E.F.; Huang, C.W.; Ewel, J.M.; Chang, A.A.; Yuan, C. Halofuginone down-regulates Smad3 expression and inhibits the TGFβ-induced expression of fibrotic markers in human corneal fibroblasts. Mol. Vis. 2012, 18, 479-487.
53. Halevy, O.; Nagler, A.; Levi-Schaffer, F.; Genina, O.; Pines, M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone. Biochem. Pharmacol. 1996, 52, 1057-1063.
54. Levi-Schaffer, F.; Nagler, A.; Slavin, S.; Knopov, V.; Pines, M. Inhibition of collagen synthesis and changes in skin morphology in murine graft versus host disease and tight skin mice: Effect of halofuginone. J. Investig. Dermatol. 1996, 106, 84-88.
55. Pines, M.; Domb, A.; Ohana, M.; Inbar, J.; Genina, O.; Alexiev, R.; Nagler, A. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem. Pharmacol. 2001, 62, 1221-1227.
56. Nagler, A.; Firman, N.; Feferman, R.; Cotev, S.; Pines, M.; Shoshan, S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am. J. Respir. Crit. Care Med. 1996, 154, 1082-1086.
57. Nagler, A.; Rivkind, A.I.; Raphael, J.; Levi-Schaffer, F.; Genina, O.; Lavelin, I.; Pines, M. Halofuginone-An inhibitor of collagen type I synthesis-Prevents postoperation abdominal adhesions formation. Ann. Surg. 1998, 227, 575-582.
58. Nagler, A.; Genina, O.; Lavelin, I.; Ohana, M.; Pines, M. Halofuginone, an inhibitor of collagen type I synthesis, prevents formation of postoperative adhesions formation in the rat uterine horn model. Am. J. Obstet. Gynecol. 1999, 180, 558-563.
59. Nagler, A.; Gofrit, O.; Ohana, M.; Pode, D.; Genina, O.; Pines, M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: In vivo and in vitro study in a rat model. J. Urol . 2000, 164, 1776-1780.
60. Pines, M.; Knopov, V.; Genina, O.; Lavelin, I.; Nagler, A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 1997, 26, 391-398.
61. Gnainsky, Y.; Spira, G.; Paizi, M.; Bruck, R.; Nagler, A.; Naffer Abu-Amar, S.; Geiger, B.; Genina, O.; Monsonego-Ornan, E.; Pines, M. Halofuginone-An inhibitor of collagen synthesis by rat stellate cells-Stimulates insulin-like growth factor binding protein 1 synthesis by hepatocytes. J. Hepatol. 2004, 40, 269-277.
62. Zion, O.; Genin, O.; Kawada, N.; Yoshizato, K.; Roffe, S.; Nagler, A.; Iovanna, J.L.; Halevy, O.; Pines, M. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 2009, 38, 427-435.
63. Bruck, R.; Genina, O.; Aeed, H.; Alexiev, R.; Nagler, A.; Pines, M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001, 33, 379-386.
64. Huebner, K.D.; Jassal, D.S.; Halevy, O.; Pines, M.; Anderson, J.E. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H1550-H1561.
65. Spira, G.; Mawasi, N.; Paizi, M.; Anbinder, N.; Genina, O.; Alexiev, R.; Pines, M. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J. Hepatol . 2002, 37, 331-339.
66. Popov, Y.; Patsenker, E.; Bauer, M.; Niedobitek, E.; Schulze-Krebs, A.; Schuppan, D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J. Biol. Chem. 2006, 281, 15090-15098.
67. Zacharia, E.; Atzmon, R.; Nagler, A.; Shimoni, A.; Peretz, T.; Vlodavsky, I.; Nagler, A. Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anticancer Drugs 2012, 23, 1022-1031.
68. Verrecchia, F.; Mauviel, A. Transforming growth factor-beta and fibrosis. World J. Gastroenterol. 2007, 13, 3056-3062.
69. Kamato, D.; Burch, M.L.; Piva, T.J.; Rezaei, H.B.; Rostam, M.A.; Xu, S.; Zheng, W.; Little, P.J.; Osman, N. Transforming growth factor-β signalling: Role and consequences of Smad linker region phosphorylation. Cell. Signal. 2013, 25, 2017-2024.
70. McGaha, T.L.; Phelps, R.G.; Spiera, H.; Bona, C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Investig. Dermatol. 2002, 118, 461-470.
71. Turgeman, T.; Hagai, Y.; Huebner, K.; Jassal, D.S.; Anderson, J.E.; Genin, O.; Nagler, A.; Halevy, O.; Pines, M. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul. Disord. 2008, 18, 857-868.
72. Gnainsky, Y.; Kushnirsky, Z.; Bilu, G.; Hagai, Y.; Genina, O.; Volpin, H.; Bruck, R.; Spira, G.; Nagler, A.; Kawada, N.; et al. Gene expression during chemically induced liver fibrosis: Effect of halofuginone on TGF-β signaling. Cell Tissue Res. 2007, 328, 153-166.
73. Roffe, S.; Hagai, Y.; Pines, M.; Halevy, O. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: Effect on myotube fusion. Exp. Cell Res. 2010, 316, 1061-1069.
74. Spector, I.; Zilberstein, Y.; Lavy, A.; Nagler, A.; Genin, O.; Pines, M. Involvement of host stroma cells and tissue fibrosis in pancreatic tumor development in transgenic mice. PLoS One 2012, 7, e41833.
75. Guo, L.W.; Wang, B.; Goel, S.A.; Little, C.; Takayama, T.; Shi, X.D.; Roenneburg, D.; DiRenzo, D.; Kent, K.C. Halofuginone stimulates adaptive remodeling and preserves re-endothelialization in balloon-injured rat carotid arteries. Circ. Cardiovasc. Interv. 2014, 7, 594-601.
76. Nevo, Y.; Halevy, O.; Genin, O.; Turgeman, T.; Harel, M.; Biton, E.; Reif, S.; Pines, M. Inhibition of fibrosis in laminin-α2-deficient congenital muscular dystrophy mice: Effect of halofuginone. Muscle Nerve 2010, 4, 218-229.
77. Halevy, O.; Genin, O.; Barzilai-Tutsch, H.; Pima, Y.; Levi, O.; Moshe, I.; Pines, M. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone. Histol. Histopathol. 2013, 28, 211-226.
78. Fromes, Y.; Bouyon, S.; Nagi, S.; Roussel, V.; Genin, O.; Levi, O.; Halevy, O.; Pines, M. Inhibition of fibrosis and improving function of the myopathic hamster cardiac muscle by halofuginone. J. Exp. Clin. Cardiol. 2014, 20, 2351-2383.
79. Genin, O.; Rechavi, G.; Nagler, A.; Ben-Itzhak, O.; Nazemi, K.; Pines, M. Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: A novel target for treatment? Neoplasia 2008, 10, 940-948.
80. Elkin, M.; Miao, H.Q.; Nagler, A.; Aingorn, E.; Reich, R.; Hemo, I.; Dou, H.L.; Pines, M.; Vlodavsky, I. Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000, 14, 2477-2485.
81. Abramovitch, R.; Dafni, H.; Neeman, M.; Nagler, A.; Pines, M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999, 1, 321-329.
82. Elkin, M.; Ariel, I.; Miao, H.Q.; Nagler, A.; Pines, M.; de-Groot, N.; Hochberg, A.; Vlodavsky, I. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res. 1999, 59, 4111-4118.
83. Pinthus, J.H.; Sheffer, Y.; Nagler, A.; Fridman, E.; Mor, Y.; Genina, O.; Pines, M. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J. Urol. 2005, 174, 1527-1531.
84. Van Kempen, L.C.; Rijntjes, J.; Mamor-Cornelissen, I.; Vincent-Naulleau, S.; Gerritsen, M.J.; Ruiter, D.J.; van Dijk, M.C.; Geffrotin, C.; van Muijen, G.N. Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int. J. Cancer 2008, 122, 1019-1029.
85. Spector, I.; Honig, H.; Kawada, N.; Nagler, A.; Genin, O.; Pines, M. Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas 2010, 39, 1008-1015.
86. Gavish, Z.; Pinthus, J.H.; Barak, V.; Ramon, J.; Nagler, A.; Eshhar, Z.; Pines, M. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 2002, 51, 73-83.
87. Taras, D.; Blanc, J.F.; Rullier, A.; Dugot-Senant, N.; Laurendeau, I.; Bièche, I.; Pines, M.; Rosenbaum, J. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 2006, 8, 312-318.
88. Juárez, P.; Mohammad, K.S.; Yin, J.J.; Fournier, P.G.; McKenna, R.C.; Davis, H.W.; Peng, X.H.; Niewolna, M.; Javelaud, D.; Chirgwin, J.M.; et al. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res. 2012, 72, 6247-6256.
89. Sheffer, Y.; Leon, O.; Pinthus, J.H.; Nagler, A.; Mor, Y.; Genin, O.; Iluz, M.; Kawada, N.; Yoshizato, K.; Pines, M. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol. Cancer Ther. 2007, 6, 570-577.
90. Ashkenazi, A.; Salvesen, G. Regulated cell death: Signaling and mechanisms. Ann. Rev. Cell Dev. Biol. 2014, 30, 337-356.
91. Grudzien, M.M.; Low, P.S.; Manning, P.C.; Arredondo, M.; Belton, R.J., Jr.; Nowak, R.A. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil. Steril. 2010, 93, 1290-1298.
92. De Figueiredo-Pontes, L.L.; Assis, P.A.; Santana-Lemos, B.A.; Jácomo, R.H.; Lima, A.S.; Garcia, A.B.; Thomé, C.H.; Araújo, A.G.; Panepucci, R.A.; Zago, M.A.; et al. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One 2011, 6, e26713.
93. Leiba, M.; Jakubikova, J.; Klippel, S.; Mitsiades, C.S.; Hideshima, T.; Tai, Y.T.; Leiba, A.; Pines, M.; Richardson, P.G.; Nagler, A.; et al . Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br. J. Haematol. 2012, 157, 718-731.
94. Chu, T.L.; Guan, Q.; Nguan, C.Y.; Du, C. Halofuginone suppresses T cell proliferation by blocking proline uptake and inducing cell apoptosis. Int. Immunopharmacol. 2013, 16, 414-423.
95. Jin, M.L.; Park, S.Y.; Kim, Y.H.; Park, G.; Lee, S.J. Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9. Int. J. Oncol. 2014, 44, 309-318.
96. Bodanovsky, A.; Guttman, N.; Barzilai-Tutsch, H.; Genin, O.; Levy, O.; Pines, M.; Halevy, O. Halofuginone improves muscle-cell survival in muscular dystrophies. Biochim. Biophys. Acta 2014, 1843, 1339-1347.
97. Singh, R.P.; Hasan, S.; Sharma, S.; Nagra, S.; Yamaguchi, D.T.; Wong, D.; Bh, H.; Hossain, A. Th17 cells in inflammation and autoimmunity. Autoimmun. Rev. 2014, 13, 1174-1181.
98. Shabgah, A.G.; Fattahi, E.; Shahneh, F.Z. Interleukin-17 in human inflammatory diseases. Postepy Dermatol. Alergol. 2014, 31, 256-261.
99. Sundrud, M.S.; Koralov, S.B.; Feuerer, M.; Calado, D.P.; Kozhaya, A.E.; Rhule-Smith, A.; Lefebvre, R.E.; Unutmaz, D.; Mazitschek, R.; Waldner, H.; et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009, 324, 1334-1338.
100. Peng, W.; Robertson, L.; Gallinetti, J.; Mejia, P.; Vose, S.; Charlip, A.; Chu, T.; Mitchell, J.R. Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3002629.
101. Pietrella, D.; Rachini, A.; Pines, M.; Pandey, N.; Mosci, P.; Bistoni, F.; d'Enfert, C.; Vecchiarelli, A. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 2011, 6, e22770.
102. Deselm, C.J.; Zou, W.; Teitelbaum, S.L. Halofuginone prevents estrogen-deficient osteoporosis in mice. J. Cell. Biochem. 2012, 113, 3086-3092.
103. Park, M.K.; Park, J.S.; Park, E.M.; Lim, M.A.; Kim, S.M.; Lee, D.G.; Baek, S.Y.; Yang, E.J.; Woo, J.W.; Lee, J.; et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. Arthritis Rheumatol. 2014, 66, 1195-1207.
104. Cheng, H.; Tian, J.; Zeng, L.; Pan, B.; Li, Z.; Song, G.; Chen, W.; Xu, K. Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation. Hematology 2012, 17, 261-267.
105. Keller, T.L.; Zocco, D.; Sundrud, M.S.; Hendrick, M.; Edenius, M.; Yum, J.; Kim, Y.J.; Lee, H.K.; Cortese, J.F.; Wirth, D.F.; et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem. Biol. 2012, 8, 311-317.
106. Son, J.; Lee, E.H.; Park, M.; Kim, J.H.; Kim, J.; Kim, S.; Jeon, Y.H.; Hwang, K.Y. Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone. Acta Crystallogr. D Biol. Crystallogr. 2013, 69, 2136-2145.
107. Hernández, A.S. Helper (TH1, TH2, TH17) and regulatory cells (Treg, TH3, NKT) in rheumatoid arthritis. Reumatol. Clin. 2009, 5 (Suppl. S1), 1-5.
108. Ho, A.W.; Gaffen, S.L. IL-17RC: A partner in IL-17 signaling and beyond. Semin. Immunopathol. 2010, 32, 33-42.
109. Veldhoen, M.; Hocking, R.J.; Atkins, C.J.; Locksley, R.M.; Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24, 179-189.
110. Edwards, J.P.; Fujii, H.; Zhou, A.X.; Creemers, J.; Unutmaz, D.; Shevach, E.M. Regulation of the expression of GARP/latent TGF-β1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J. Immunol. 2013, 190, 5506-5515.
111. Zhou, L.; Lopes, J.E.; Chong, M.M.; Ivanov, I.I.; Min, R.; Victora, G.D.; Shen, Y.; Du, J.; Rubtsov, Y.P.; Rudensky, A.Y.; et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORct function. Nature 2008, 453, 236-240.
112. Malhotra, N.; Kang, J. SMAD regulatory networks construct a balanced immune system. Immunology 2013, 139, 1-10.
113. Pinchuk, I.V.; Morris, K.T.; Nofchissey, R.A.; Earley, R.B.; Wu, J.Y.; Ma, T.Y.; Beswick, E.J. Stromal cells induce Th17 during Helicobacter pylori infection and in the gastric tumor microenvironment. PLoS One 2013, 8, e53798.
114. Liang, J.; Zhang, B.; Shen, R.W.; Liu, J.B.; Gao, M.H.; Geng, X.; Li, Y.; Li, Y.Y.; Zhang, W. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis. Scand. J. Immunol . 2014, 79, 163-172.
115. Ghoreschi, K.; Laurence, A.; Yang, X.P.; Tato, C.M.; McGeachy, M.J.; Konkel, J.E.; Ramos, H.L.; Wei, L.; Davidson, T.S.; Bouladoux, N.; et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature 2010, 467, 967-971.
116. Coombes, J.L.; Siddiqui, K.R.R.; Arancibia-Cárcamo, C.V.; Hall, J.; Sun, C.M.; Belkaid, Y.; Powrie, F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism. J. Exp. Med. 2007, 204, 1757-1764.
117. Meis, J.F.; Ponnudurai, T.; Mons, B.; van Belkum, A.; van Eerd, P.M.; Druilhe, P.; Schellekens, H. Plasmodium falciparum: Studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp. Parasitol. 1990, 70, 1-11.
118. Vanderberg, J.P.; Khan, Z.M.; Stewart, M.J. Induction of hepatic inflammatory response by Plasmodium berghei sporozoites protects BALB/c mice against challenge with Plasmodium yoelii sporozoites. J. Parasitol . 1993, 79, 763-767.
119. Khan, Z.M.; Vanderberg, J.P. Specific inflammatory cell infiltration of hepatic schizonts in BALB/c mice immunized with attenuated Plasmodium yoelii sporozoites. Int. Immunol. 1992, 4, 711-718.
120. Wong, G.L. Prediction of fibrosis progression in chronic viral hepatitis. Clin. Mol. Hepatol. 2014, 20, 228-236.
121. Schacker, T.W.; Nguyen, P.L.; Beilman, G.J.; Wolinsky, S.; Larson, M.; Reilly, C.; Haase, A.T. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J. Clin. Investig. 2002, 110, 1133-1139.
122. Nagler, A.; Pines, M. Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: A novel inhibitor of collagen type I synthesis. Transplantation 1999, 68, 1806-1809.
123. Koon, H.B.; Fingleton, B.; Lee, J.Y.; Geyer, J.T.; Cesarman, E.; Parise, R.A.; Egorin, M.J.; Dezube, B.J.; Aboulafia, D.; Krown, S.E. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 2011, 56, 64-68.
124. Pines, M.; Snyder, D.; Yarkoni, S.; Nagler, A. Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma. Biol. Blood Marrow Transplant. 2003, 9, 417-425.
125. De Jonge, M.J.; Dumez, H.; Verweij, J.; Yarkoni, S.; Snyder, D.; Lacombe, D.; Marréaud, S.; Yamaguchi, T.; Punt, C.J.; van Oosterom, A. EORTC New Drug Development Group (NDDG). Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 2006, 42, 1768-1774.
126. Leiba, M.; Cahalon, L.; Shimoni, A.; Lider, O.; Zanin-Zhorov, A.; Hecht, I.; Sela, U.; Vlodavsky, I.; Nagler, A. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J. Leukoc. Biol. 2006, 80, 399-406.